Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Soleno Therapeutics, Inc. - Common Stock (NQ:SLNO)

53.01 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 53.01
Bid (Size) 53.00 (500)
Ask (Size) 53.03 (500)
Prev. Close 53.01
Today's Range 53.01 - 53.01
52wk Range 29.43 - 72.80
Shares Outstanding 8,168,788
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNO
From Pomerantz LLP
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether SLNO, OGN, RMAX, XOMA are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire

Performance

52-Week Range 27.2% below 52-week high
53.01
29.4352W Low 72.8052W High

Soleno Therapeutics, Inc. - Common Stock (SLNO) traded between $29.43 and $72.80 over the past 52 weeks and last traded at $53.01, 27.2% below its 52-week high.

Past 12 Months
N/A
N/A
N/A
+0.6%
+12.4%
-19.0%
1W  
1M  
3M  
6M +$0.34
YTD +$5.84
1Y -$12.44

SLNO was -19.0% over the past year, +0.6% over six months, +12.4% year to date.

12 Months vs Market
SLNO
-19.0%
DIA
+11.2%
SPY
+14.4%
QQQ
+17.7%
IWM
+9.3%

Over the past 12 months SLNO returned -19.0% versus DIA (Dow) +11.2%, SPY (S&P 500) +14.4%, QQQ (Nasdaq 100) +17.7% and IWM (Russell 2000) +9.3%.

Volume & Liquidity
6M
1.7M
YTD
2.8M
1Y
2.4M

More News

Read More
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
From Brodsky & Smith LLC
Via GlobeNewswire
Soleno Therapeutics Inc (NASDAQ:SLNO): A Decent Value Play with Strong Health and Explosive Growth Potential ↗
Via Chartmill
News headline image
Halper Sadeh LLC is Investigating Whether SLNO, APLS, HLX are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
SOLENO THERAPEUTICS CLASS ACTION DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Soleno Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before May 5th Lead Plaintiff Deadline
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
SOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Deadline Soon: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
SOLENO THERAPEUTICS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Soleno Therapeutics 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Soleno Therapeutics, Inc. - SLNO
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Soleno Therapeutics, Inc. - SLNO
From SkyMedia, LLC
Via GlobeNewswire
News headline image
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
SOLENO THERAPEUTICS, INC. (SLNO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Soleno Therapeutics, Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Soleno Therapeutics, Inc. Notice of May 5, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
From Kahn Swick & Foti, LLC
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNO
From Pomerantz LLP
Via GlobeNewswire
News headline image
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Soleno Therapeutics, Inc. (SLNO)
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether OGN, XOMA, RMAX, SLNO are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Bragar Eagel & Squire, P.C. Urges Soleno Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before May 5th Lead Plaintiff Deadline
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
SLNO Deadline: Rosen Law Firm Urges Soleno Therapeutics, Inc. (NASDAQ: SLNO) Stockholders to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Soleno Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Soleno Therapeutics, Inc. - SLNO
From SkyMedia, LLC
Via GlobeNewswire
News headline image
SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Shareholder Alert: The Ademi Firm investigates whether Soleno Therapeutics Inc.’s Transaction with Neurocrine is Fair to Public Shareholders
From Ademi LLP
Via GlobeNewswire

Frequently Asked Questions

Is Soleno Therapeutics, Inc. - Common Stock publicly traded?
Yes, Soleno Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Soleno Therapeutics, Inc. - Common Stock trade on?
Soleno Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Soleno Therapeutics, Inc. - Common Stock?
The ticker symbol for Soleno Therapeutics, Inc. - Common Stock is SLNO on the Nasdaq Stock Market
What is the current price of Soleno Therapeutics, Inc. - Common Stock?
The current price of Soleno Therapeutics, Inc. - Common Stock is 53.01
When was Soleno Therapeutics, Inc. - Common Stock last traded?
The last trade of Soleno Therapeutics, Inc. - Common Stock was at 05/15/26 04:00 PM ET
What is the market capitalization of Soleno Therapeutics, Inc. - Common Stock?
The market capitalization of Soleno Therapeutics, Inc. - Common Stock is 433.03M
How many shares of Soleno Therapeutics, Inc. - Common Stock are outstanding?
Soleno Therapeutics, Inc. - Common Stock has 433M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.